Telix Pharmaceuticals Limited announced alignment with the FDA to advance its ProstACT Global Phase 3 clinical trial. The company filed an announcement with the Australian Securities Exchange on July 2, 2026, regarding this regulatory progress. Telix Pharmaceuticals is a radiopharmaceutical company focused on developing diagnostic and therapeutic solutions.
